Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 97 from CROI 2016
Tuberculosis: Why Do I Have to Take So Many Pills?
Eric J. Rubin
Harvard School of Public Health, Boston, MA, United States
from CROI 2016 on February 25, 2016 8:30 AM-9:00 AM
The Evolving Epidemiology of HIV Infection in Persons Who Inject Drugs: Indiana 2015
John T. Brooks
Centers for Disease Control and Prevention, Atlanta, GA, United States
from CROI 2016 on February 25, 2016 9:00 AM-9:30 AM
SIV-Infected Brain Macrophages Leave the Central Nervous System
Xavier Alvarez
Tulane National Primate Research Center, Covington, LA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
CSF Lymphocyte and Monocyte Activation and Trafficking in Primary HIV Infection
Xiang Li
Yale University School of Medicine, New Haven, CT, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Compartmentalized HIV DNA Populations Persist in CSF Despite Suppressive ART
Michelli Faria de Oliveira
University of California San Diego, San Diego, CA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Mitochondrial DNA Copy Number and Neurocognitive Impairment in HIV-Infected Persons
David Samuels
Vanderbilt University School of Medicine, Nashville, TN, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Lipid Profiles and APOE4 Allele Impact Midlife Cognitive Decline in HIV+ Men on ART
Shibani S. Mukerji
Massachusetts General Hospital, Boston, MA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Paroxetine and Fluconazole Therapy for HAND: A Double-Blind, Placebo-Controlled Trial
Ned Sacktor
Johns Hopkins University School of Medicine, Baltimore, MD, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
MVC and TDF Reduce Neurocognitive Impairment in Initial ART: ACTG A5303
Kevin R. Robertson
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Brain MRI Changes Associated With Poorer Cognitive Function in Treated HIV Infection
Jonathan Underwood
Imperial College London, London, United Kingdom
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Isolated Seminal HIV-1 RNA Shedding in African Men With Uninfected Women Partners
Andrew Mujugira
University of Washington, Seattle, WA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Exploring the Effectiveness of Traditional Circumcision Practices in Preventing HIV
Michael Pickles
Imperial College London, London, United Kingdom
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
2013-14 Rwanda HIV Incidence Household Survey: Understanding HIV Epidemic in Rwanda
Eric Remera
Institute of HIV/AIDS Disease Prevention and Control, Rwanda Biomedical Center, Kigali, Rwanda
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Antiretroviral Therapy and HIV Acquisition in a South African Population-Based Cohort
Catherine Oldenburg
Harvard School of Public Health, Boston, MA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Option B+ in Malawi: Have 4 Years of "Treat All" Shown That 90-90-90 Is Achievable?
Andreas Jahn
Ministry of Health, Lilongwe, Malawi
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Measuring the Impact of Test & Treat on the HIV Cascade: The Challenge of Mobility
Joseph Larmarange
Centre Population et Développement, Paris, France
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
HIV-1 Infection With Multiclass Resistance Despite Preexposure Prophylaxis (PrEP)
David C. Knox
Maple Leaf Medical Clinic, Toronto, ON, Canada
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Gel Applied as Anal Lube Without Applicator Provides Poor Rectal Mucosal HIV Coverage
Eugenie Shieh
Johns Hopkins University, Baltimore, MD, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Oral Abstract Moderator
Arthur Y. Kim
Harvard Medical School, Boston, MA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Networks of HCV Transmissions Among Persons Who Inject Drugs: Indiana, 2015
Sumathi Ramachandran
Centers for Disease Control and Prevention, Atlanta, GA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Hepatitis B and C, Alcohol, and CD4 Drive End-Stage Liver Disease in HIV+ Adults
Keri N. Althoff
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Antiretroviral Therapy Reduces Intrahepatic Hepatitis C in HIV-1/HCV Coinfection
Ashwin Balagopal
Johns Hopkins University, Baltimore, MD, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Broadly Neutralizing Antibodies Avert HCV ReInfection or Subsequent Chronic Infection
Sabrina J. Merat
AIMM Therapeutics, Amsterdam, Netherlands
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
High Response Rate in HCV-Genotype 4 Patients Treated With Ravidasvir and Sofosbuvir
Imam Waked
National Liver Institute, Shebeen El Kom, Egypt
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Ledipasvir/Sofosbuvir for 6 Weeks in HIV-Infected Patients With Acute HCV Infection
Jürgen K. Rockstroh
Medizinische Universitatsklinik, Bonn, Germany
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Type 1 Interferon Resistance Is a Hallmark of Mucosally Transmitted HIV-1
Frederic Bibollet-Ruche
University of Pennsylvania, Philadelphia, PA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Expression and Potency of IFNa Subtypes in an Ex Vivo Model of Acute HIV-1 Infection
Mario L. Santiago
University of Colorado Anschutz Medical Campus, Aurora, CO, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Novel Mechanism of Interferon Restriction of HIV-1 in Humans
Ramy El-Diwany
Johns Hopkins University, Baltimore, MD, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
SERINC3 and SERINC5 Are Novel Antiviral Proteins Antagonized by HIV-1 Nef
Yuanfei Wu
University of Massachusetts Medical School, Worcester, MA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
The PPIP122-125 Motif in HIV-1 CA Is an Essential Assembly and Maturation Element
Mariia Novikova
National Cancer Institute, Frederick, MD, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Characterization of 2 CCR5 Tropic HIV-1 Viruses Exhibiting High Env Content
Sean P. O'Brien
Leidos Biomedical Research, Frederick, MD, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Nuclear Entry of HIV Requires Reshaping of Integrase Multimers
Zeger Debyser
Katholieke Universiteit Leuven, Leuven, Belgium
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
1970s HIV-1 Genomes Reveal the Early History of the North American HIV/AIDS Epidemic
Michael Worobey
University of Arizona, Tucson, AZ, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Oral Abstract Moderator
Andrew Kambugu
Infectious Diseases Institute, Kampala, Uganda
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Empirical TB Treatment in Advanced HIV Disease: Results of the TB Fast Track Trial
Alison Grant
London School of Hygiene & Tropical Medicine, London, United Kingdom
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Acceptability of Large-Scale Household-Based TB Screening: HPTN 071 (PopART) Trial
Comfort Rutty Phiri
Zambia AIDS Related Tuberculosis Project (ZAMBART), Lusaka, Zambia
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
HIV-Associated XDR TB Is Transmitted in Households and Hospitals in South Africa
Sara C. Auld
Emory University, Atlanta, GA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Beta-Lactams Against TB: Teaching a New Trick to an Old Dog
Andreas H. Diacon
Stellenbosch University, Bellville, South Africa
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Pre-ART Cryptococcal Antigen Titer Associated With Preemptive Fluconazole Failure
Bozena M. Morawski
University of Minnesota, Minneapolis, MN, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Immediate ART Initiation Reduces Risk of Infection-Related Cancer in HIV Infection
Alvaro H.D. Borges
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
ACTG A5298: A Phase 3 Trial of the Quadrivalent HPV Vaccine in Older HIV+ Adults
Timothy J. Wilkin
Weill Cornell Medical College, New York, NY, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Is Intensive Cervical Cancer Screening Justified in Immunosuppressed Women?
Michael J. Silverberg
Kaiser Permanente Northern California, Oakland, CA, United States
from CROI 2016 on February 25, 2016 10:00 AM-12:00 PM
Discussion of Plenary Session 6 – The Evolving Epidemiology of HIV Infection in Persons Who Inject Drugs: Indiana 2015 and Oral Abstract Session 13 – HCV: Curing the Patient but Not the Population
Chair
Harold W. Jaffe
US Centers for Disease Control and Prevention, Atlanta, GA, United States
PL6: The Evolving Epidemiology of HIV Infection in Persons Who Inject Drugs: Indiana 2015
John Brooks
US Centers for Disease Control and Prevention, Atlanta, GA, United States
OA13: Networks of HCV Transmissions Among Persons Who Inject Drugs: Indiana, 2015
Sumathi Ramachandran
US Centers for Disease Control and Prevention, Atlanta, GA, United States
from CROI 2016 on February 25, 2016 12:30 PM-1:30 PM
Discussion of Oral Abstract Session 14 – Tuberculosis and Other Opportunistic Infections/Cancer Prevention: Hits and Misses
Chair
Richard Chaisson
Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, MD, United States
OA14: Empirical TB Treatment in Advanced HIV Disease: Results of the TB Fast Track Trial
Alison Grant
London School of Hygiene & Tropical Medicine, London, United Kingdom
OA14: Acceptability of Large-Scale Household-Based TB Screening: HPTN 071 (PopART)
Comfort R. Phiri
ZAMBART, Lusaka, Zambia
OA14: HIV-Associated XDR TB Is Transmitted in Households and Hospitals in South Africa
Sara C. Auld
Emory University, Atlanta, GA, United States
OA14: Pre-ART Cryptococcal Antigen Titer Associated With Preemptive Fluconazole Failure
Bozena M. Morawski
University of Minnesota, Minneapolis, MN, United States
from CROI 2016 on February 25, 2016 12:30 PM-1:30 PM
Themed Discussion Leader
Anne Cori
Imperial College London, London, United Kingdom
from CROI 2016 on February 25, 2016 1:45 PM-2:45 PM
Effect of Eliminating CD4 Thresholds on Number of New ART Initiators in South Africa
Jacob Bor
Boston University School of Public Health, Boston, MA, United States
from CROI 2016 on February 25, 2016 1:45 PM-2:45 PM
Optimizing Resource Allocation to Reduce HIV Incidence Across Sub-Saharan Africa
Jessica B. McGillen
Imperial College London, London, United Kingdom
from CROI 2016 on February 25, 2016 1:45 PM-2:45 PM
New ARVs Could Represent More Than USD 3 Billion in Cost Savings Through 2025
Vineet R. Prabhu
Clinton Health Access Initiative, Boston, MA, United States
from CROI 2016 on February 25, 2016 1:45 PM-2:45 PM
Impact of Improving HIV Care and Treatment and Initiating PrEP in the US, 2015-2020
Emine Yaylali
Centers for Disease Control and Prevention, Atlanta, GA, United States
from CROI 2016 on February 25, 2016 1:45 PM-2:45 PM
PrEP Is Only Cost-Effective Among MSM in the Netherlands When Used on Demand
Brooke E. Nichols
Erasmus University Medical Center, Rotterdam, Netherlands
from CROI 2016 on February 25, 2016 1:45 PM-2:45 PM
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 50 of 97 from CROI 2016